Company
Tridek-One
Tridek-One develops first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases
Also known as Tridek-One SAS
- Status
- Operatingas of 2026-09-21
- Business model
- B2B
- Headquarters
- Paris, France
- Legal name
- Tridek-One SAS
Claim, correct or request removal
Record updated 28 September 2026
About
Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases.
Funding snapshot
- Latest round
- Undisclosed
Funding rounds
- Round
- Recorded
Loading relationship preview